BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

 
• By Alaric DeArment

The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic. The firm stressed growth opportunities ahead for Opdivo, Opdualag and Camzyos.

earnings report
BMS announced its first quarter earnings on 29 April • Source: Shutterstock

More from Business

More from Scrip